Ventricular Tachycardia Management

Introduction

• Ventricular tachycardia (VT) management involves a combination of pharmacological, device-based, and catheter ablation interventions, as recommended by the European Society of Cardiology and the American Heart Association 1, 2

Pharmacological Therapy

• Beta-blockers are the first-line pharmacological therapy for patients with structural ventricular tachycardia (VT), with amiodarone being the most effective antiarrhythmic drug for preventing recurrent VT episodes when beta-blockers alone are insufficient, according to the American Heart Association 3
• Beta-blockers are particularly effective for polymorphic VT and VT associated with ischemia, as recommended by the European Society of Cardiology 1
• Amiodarone is the most effective antiarrhythmic for secondary prevention of VT in structural heart disease, with a recommended maintenance dose of 300-400 mg daily, as suggested by the European Society of Cardiology 4
• IV procainamide is recommended as a first-line treatment for sustained monomorphic VT, with a loading dose of 20-30mg/min up to 12-17mg/kg, followed by 1-4mg/min infusion, as suggested by the European Society of Cardiology 1
• IV amiodarone is an alternative option, particularly for patients with heart failure, as recommended by the European Society of Cardiology 5, 1
• IV lidocaine is considered for VT associated with acute myocardial ischemia, according to the European Society of Cardiology 1
• IV beta-blockers are considered for polymorphic VT or if ischemia is suspected, as suggested by the European Society of Cardiology 1
• Intravenous amiodarone is effective for recurrent or incessant VT, with a dose of 150 mg IV over 10 minutes, followed by 1 mg/min for 6 hours, then 0.5 mg/min, as recommended by the European Society of Cardiology with a strength of evidence classified as Class IIa 6, 1, 7
• Beta-blockers are effective for VT storm and are recommended as first-line treatment for most arrhythmias, with a strength of evidence classified as Class I 5, 8
• Procainamide is recommended as a first-line treatment for VT without severe congestive heart failure (CHF) or acute myocardial infarction (MI), with a loading infusion of 20-30 mg/min up to 12-17 mg/kg, followed by 1-4 mg/min infusion, as recommended by the European Society of Cardiology and the American College of Cardiology with a strength of evidence classified as Class IIa 6, 1, 7
• Lidocaine is particularly useful when VT is associated with acute myocardial ischemia or infarction, with a bolus dose of 1.0-1.5 mg/kg and a follow-up infusion of 2-4 mg/min, as recommended by the American College of Cardiology with a strength of evidence classified as Class IIb 6, 1
• Sotalol may be considered for stable monomorphic VT, including patients with acute myocardial infarction, but caution is advised due to its significant beta-blocking properties, as recommended by the American College of Cardiology with a strength of evidence classified as Class IIb 9, 7
• Magnesium may be administered as an 8 mmol bolus followed by 2.5 mmol/h infusion, particularly when VT is associated with acute myocardial infarction, according to the British Journal of Sports Medicine with a strength of evidence classified as Class IIb 10

Electrolyte Management

• Electrolyte abnormalities, particularly hypokalemia and hypomagnesemia, should be corrected as they can worsen ventricular arrhythmias, as recommended by the European Society of Cardiology 1
• Serum potassium levels should be maintained above 4.0 mM/L to prevent ventricular arrhythmias, as suggested by the European Society of Cardiology 1

Device Therapy

• ICD implantation is a Class I recommendation for survivors of VT/VF episodes, as recommended by the European Society of Cardiology 5
• ICD implantation is also recommended for patients with structural heart disease, LVEF ≤35%, and reasonable life expectancy, although the specific guideline society is not mentioned in this instance 5
• Implantable cardioverter-defibrillator (ICD) therapy is recommended for patients with left ventricular ejection fraction (LVEF) ≤35% and reasonable life expectancy, as well as for recurrent VT despite optimal medical therapy, with a strength of evidence classified as Class I 5, 1, 11

Catheter Ablation

• Urgent catheter ablation is a Class I recommendation for incessant VT or electrical storm resulting in ICD shocks, as recommended by the European Society of Cardiology 5
• Urgent catheter ablation is also recommended for recurrent ICD shocks despite antiarrhythmic medications, according to the European Society of Cardiology 5
• Elective catheter ablation should be considered for recurrent monomorphic VT despite optimal medical therapy, as suggested by the European Society of Cardiology 5
• Catheter ablation can be considered for patients with recurrent arrhythmias, with a success rate of 49-81% and freedom from VT at 6 months of 46-53%, as reported in the Multicenter Thermocool, Cooled RF Multi Center, Euro-VT, and SMASH-VT studies 5, 1
• The following table summarizes the outcomes of catheter ablation for scar-related VT:

5, 1

Special Considerations

• Sodium channel blockers (Class I agents) generally have a limited role in structural heart disease due to increased mortality risk, as reported by the American Heart Association 3
• Beta-blockers may increase the risk of death in patients with shock risk (age >70 years, heart rate >110 beats/min, systolic blood pressure <120 mmHg), as reported by the European Society of Cardiology with a strength of evidence classified as Class IIa 5
• For patients with ischemic cardiomyopathy and VT, ICD implantation, beta-blockers, and consideration of amiodarone for recurrent episodes and catheter ablation for recurrent ICD shocks are recommended, according to the European Society of Cardiology 5
• For patients with non-ischemic cardiomyopathy and VT, ICD implantation, optimization of heart failure medications, beta-blockers and/or amiodarone, and consideration of catheter ablation for recurrent episodes are recommended, as suggested by the European Society of Cardiology 5
• For patients with VT associated with acute myocardial infarction, urgent revascularization, beta-blockers, and consideration of lidocaine for acute management are recommended, according to the European Society of Cardiology 1
• For pregnant patients, perform manual left uterine displacement during CPR, and consider early perimortem cesarean delivery if resuscitation is unsuccessful within 4 minutes, as recommended by the American Heart Association with a strength of evidence classified as Class I 12
• In patients with long QT syndrome (Torsades de Pointes), stop QT-prolonging medications, correct electrolyte abnormalities, administer IV magnesium, and consider pacing or isoproterenol if bradycardia is present, as recommended by the American Heart Association with a strength of evidence classified as Class I 13

Medication Discontinuation Rates

• The drug discontinuation rates are as follows:

  Medication	Discontinuation Rate at 1 Year
  Amiodarone	18.2%
  Sotalol	23.5%
  Beta-blocker alone	5.3%

Emergency Management

• For hemodynamically unstable VT, immediate synchronized cardioversion is recommended, starting with an initial energy of 100J (biphasic) or 200J (monophasic), as suggested by the American Heart Association and the European Society of Cardiology with a strength of evidence classified as Class I 14, 1
• Temporary pacing may be necessary for hemodynamically significant bradycardia, as recommended by the American College of Cardiology and the American Heart Association 2, 15